Executive Summary
This digest of 37 SEC filings reveals a day of significant leadership transitions, with several high-profile CEO and CFO departures creating a mix of opportunity and uncertainty. Key themes include a wave of CFO changes at companies like Dynatrace, Criteo, GoodRx, and Chime Financial, often coinciding with mixed financial results and lowered guidance, signaling potential strategic pivots.
Conversely, strong operational performance and strategic board appointments at companies like Target Hospitality and Symbotic point to growth-oriented governance. A notable risk cluster involves sudden, unexplained CEO departures at Transportation & Logistics Systems and BlockchAIn Digital Infrastructure, creating leadership vacuums. Overall, the market is seeing a bifurcation between well-planned successions at outperforming firms and abrupt exits at those facing headwinds, with the latter group demanding closer scrutiny. Period-over-period data highlights a trend of margin compression and lowered guidance at several firms, including Criteo and Honeywell Aerospace, despite revenue growth in some cases, suggesting rising costs or strategic investments are pressuring profitability. Insider activity, while not explicitly detailed in many filings, is inferred through the leadership changes themselves, with the departure of CFOs at underperforming companies being a potential bearish signal. Capital allocation trends show a mix of continued buybacks (Criteo) and new equity programs (Bed Bath & Beyond), indicating divergent financial strategies. Scheduled events, such as upcoming earnings calls and FDA decisions, provide a clear catalyst calendar for the coming weeks and months. The most critical developments are the CEO transition at Flutter Entertainment, which appears well-managed, and the sudden CEO exits at Transportation & Logistics Systems and BlockchAIn Digital Infrastructure, which are high-risk events. Portfolio-level patterns include a concentration of leadership changes in the tech and financial services sectors, with a notable number of CFO departures suggesting a broader trend of financial leadership turnover. The data also shows a clear divergence between companies with strong forward-looking guidance (e.g., Arcutis, Chime) and those cutting expectations (e.g., Criteo, Honeywell Aerospace), providing a clear framework for identifying outperformers and underperformers. The combination of leadership changes, financial performance, and forward-looking statements creates a rich set of actionable intelligence for investors.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from August 04, 2026.
Investment Signals (10)
- Flutter Entertainment ↓ (BULLISH)▲
CEO succession is well-planned with internal promotion of Dan Taylor, who led the International division to $9B+ revenue and $2.2B EBITDA in 2025. Q2 2026 revenue grew 3% YoY to $4,326M. This signals strong governance and continuity.
- Arcutis Biotherapeutics ↓ (BULLISH)▲
ZORYVE revenue surged 59% YoY to $129.9M, achieving net income of $15.0M vs. a $15.9M loss a year ago. Full-year 2026 guidance raised to $525-$540M. This is a clear turnaround story with accelerating commercial execution.
- Symbotic Inc. ↓ (BULLISH)▲
Revenue grew 22% YoY to $721M, swinging to a net income of $55M from a $21M loss. Adjusted EBITDA more than doubled to $95M. Q4 guidance ($760-$780M revenue) implies continued strong growth. The addition of Steve Pagliuca to the board adds strategic depth.
-
Q2 2026 revenue grew 27% YoY to $670M with a second consecutive quarter of GAAP profitability ($28M net income). Full-year guidance raised to $2.725-$2.745B. However, the CFO departure introduces near-term uncertainty, creating a potential entry point if the transition is smooth. [MIXED/BULLISH]
-
Q2 2026 revenue declined 11% YoY to $428M and net income fell 49% to $12M. Full-year guidance was lowered. Despite this, the underlying Retail Media business (ex-scope changes) grew 20%, and the company is actively buying back shares ($30M in Q2). The new CFO appointment and planned redomicile to the US are catalysts. [MIXED/BEARISH]
- Dynatrace, Inc. ↓ (MIXED)▲
Q1 FY2027 results beat expectations with total ARR up 17% to $2,136M and record new logo ARR growth of 160%+. However, full-year guidance was lowered due to FX headwinds, and the CFO announced retirement. The core business is strong, but the guidance cut and leadership change create a short-term overhang.
- Honeywell Aerospace ↓ (BEARISH)▲
Q2 2026 sales grew 5% YoY to $4.5B, but net income fell 70% and adjusted EBIT declined 7% due to separation costs. Full-year guidance was cut significantly (organic growth from 7-9% to 4-5%). The spin-off is complete, but the lowered outlook suggests near-term headwinds.
-
Q2 2026 revenue surged 66% YoY to $234.3M, driven by a 150% jump in Smallpox MCM sales. Adjusted net income improved 134%. However, a $191.3M impairment charge on NARCAN led to a massive net loss, and the Commercial Products segment (naloxone) saw a 22% revenue decline. A restructuring plan is underway. [MIXED/BEARISH]
- Target Hospitality ↓ (BULLISH)▲
Appointed two new independent directors with deep expertise in AI-driven data center and critical infrastructure, signaling a strategic pivot. Peggy Smyth (Etsy, Remitly) and Erich Sanchack (ex-COO of Digital Realty) bring highly relevant experience.
- Zillow Group ↓ (MIXED)▲
Q2 2026 revenue grew 18% YoY to $772M, driven by Mortgages (+75%) and Rentals (+31%). Adjusted EBITDA of $176M beat guidance. However, the company posted a net loss of $4M and traffic declined 2% YoY, suggesting growth is coming from higher monetization rather than audience expansion.
Risk Flags (10)
- Transportation & Logistics Systems↓ [HIGH RISK]▼
CEO and Chairman John J. Borek III departed immediately with no successor named, creating a leadership vacuum. No reason was given, which is a major governance red flag.
- BlockchAIn Digital Infrastructure↓ [HIGH RISK]▼
CEO John Smith departed suddenly with no reason stated. While an interim CEO was appointed, the lack of explanation raises serious governance concerns and suggests potential internal turmoil.
- Criteo S.A.↓ [HIGH RISK]▼
Revenue declined 11% YoY and net income fell 49%. Full-year Contribution ex-TAC guidance was lowered to -12% to -10%. Gross profit margin contracted 200 bps to 52% and adjusted EBITDA margin fell 200 bps to 29%. This is a clear deterioration in core financial health.
- Honeywell Aerospace↓ [HIGH RISK]▼
Full-year 2026 organic growth guidance was slashed from 7-9% to 4-5%, and pro forma adjusted EBIT guidance was cut from $4.65-$4.75B to $4.35-$4.45B. This significant guidance cut signals major near-term headwinds post-spin-off.
- Emergent BioSolutions↓ [HIGH RISK]▼
Net loss widened to $180.2M from $12.0M due to a $191.3M non-cash impairment charge on the NARCAN asset group. The Commercial Products segment (naloxone) saw a 22% revenue decline and gross margin collapsed to 13% from 32%, indicating severe competitive pressure.
- Editas Medicine↓ [MEDIUM RISK]▼
R&D expenses increased 25% due to EDIT-401 development, and the company's cash position, while strengthened, requires careful management to fund operations into 2028. The path to profitability is still distant and dependent on clinical success.
- Bed Bath & Beyond↓ [HIGH RISK]▼
Adopted a new equity inducement plan and entered into a sales agreement to sell up to $200M of common stock. This heavy reliance on equity financing and the 'Capital on Demand' agreement signals significant cash burn and uncertainty around the proposed Fathom Holdings transaction.
- Chime Financial↓ [MEDIUM RISK]▼
CFO Matt Newcomb is stepping down effective August 7, 2026, with only a two-day notice. While an interim CFO is in place, a sudden CFO departure at a high-growth company is a risk, especially as it navigates its path to sustained profitability.
- Dynatrace, Inc.↓ [MEDIUM RISK]▼
CFO Jim Benson's planned retirement by March 31, 2027, introduces leadership transition risk. The company also lowered its full-year ARR and revenue guidance due to a stronger dollar, creating FX headwinds that could persist.
- GoodRx Holdings, Inc.↓ [MEDIUM RISK]▼
CFO departure, while described as amicable, creates transition risk. The new CFO, Justin Fengler, is an internal hire, which mitigates some risk, but his compensation package ($1.2M in equity) is significant and his performance goals are tied to fiscal 2026, creating a short-term focus.
Opportunities (10)
- Arcutis Biotherapeutics↓ (OPPORTUNITY)◆
ZORYVE revenue grew 59% YoY and the company achieved GAAP profitability. The FDA approved a new pediatric indication, and a potential approval for infant atopic dermatitis (PDUFA Feb 2027) is a major catalyst. The stock is likely undervalued given the accelerating revenue and pipeline progress.
- Flutter Entertainment↓ (OPPORTUNITY)◆
The well-planned CEO transition to Dan Taylor, who has a proven track record of scaling the International business, provides a clear catalyst. The company's global scale and diversified revenue streams offer a defensive growth profile.
- Symbotic Inc.↓ (OPPORTUNITY)◆
Revenue growth of 22% YoY, a swing to profitability, and a strong Q4 guidance ($760-$780M revenue) point to accelerating operational leverage. The addition of Steve Pagliuca to the board could open doors to new strategic partnerships.
- Target Hospitality↓ (OPPORTUNITY)◆
The appointment of directors with deep expertise in AI data centers and critical infrastructure signals a strategic pivot into a high-growth sector. This could unlock significant value if the company successfully executes on this new strategy.
- Criteo S.A. (Contrarian)↓ (OPPORTUNITY)◆
The stock has likely sold off on the headline revenue decline and guidance cut. However, the underlying Retail Media business is growing 20% (ex-scope changes), the company is buying back shares, and the planned redomicile to the US could attract new investors. This could be a value play for patient investors.
- Zillow Group↓ (OPPORTUNITY)◆
Mortgages revenue grew 75% YoY and Rentals grew 31%, showing strong execution in higher-growth segments. The company's shift from a traffic-dependent model to a transaction-based model is working. Any pullback on the net loss or traffic decline could be a buying opportunity.
- Ivanhoe Electric↓ (OPPORTUNITY)◆
The appointment of experienced mining executives (Michelle Lammers and Daniel Worthy) ahead of the Santa Cruz Copper Project's transition to construction is a positive signal. The completion of the updated PFS in September 2026 is a key catalyst.
- Constellation Energy↓ (OPPORTUNITY)◆
The appointment of Roger Crandall (ex-Chair of the Boston Fed) as an independent director adds significant financial and risk management expertise. The elevation of CEO Joe Dominguez to Chairman signals strong alignment and a clear strategic vision.
- GoodRx Holdings, Inc.↓ (OPPORTUNITY)◆
The internal promotion of Justin Fengler to CFO provides continuity. His deep understanding of the business (since 2016) and his role as Chief Strategy & Operations Officer suggest he is well-positioned to drive operational and strategic initiatives.
- Pacific Biosciences↓ (OPPORTUNITY)◆
The officer change and associated restructuring (Item 2.05) could signal a strategic pivot to improve cost structure and focus on core growth areas. New leadership could bring a fresh perspective and drive operational improvements.
Sector Themes (6)
- Wave of CFO Departures◆
A notable cluster of CFO changes occurred across multiple sectors, including Dynatrace (retirement), Criteo (new appointment), GoodRx (departure/appointment), Chime Financial (stepping down), and Yellowstone Midco (stepping down). This suggests a broader trend of financial leadership turnover, potentially driven by strategic shifts, performance pressures, or personal decisions. Investors should scrutinize the reasons and succession plans for each.
- Bifurcation in Tech Performance◆
Tech companies in this digest show a clear split. High-growth firms like Symbotic (+22% revenue) and Zillow (+18% revenue) are outperforming, while others like Criteo (-11% revenue) and Honeywell Aerospace (+5% revenue but with significant profit decline) are facing headwinds. This highlights the importance of stock-specific analysis over sector-level bets.
- Margin Compression Despite Revenue Growth◆
Several companies reported revenue growth but experienced margin compression. Criteo's gross margin fell 200 bps, and Honeywell Aerospace's adjusted EBIT declined 7% despite 5% sales growth. This suggests rising input costs, strategic investments, or competitive pressures are eating into profitability, a key risk for growth investors.
- Strategic Board Appointments Signal Pivot◆
Companies like Target Hospitality and Constellation Energy are appointing directors with specific expertise (AI data centers, financial risk management) that signals a strategic pivot. This is a bullish indicator for investors looking for companies proactively reshaping their governance to support new growth initiatives.
- Governance Red Flags from Sudden CEO Exits◆
The sudden, unexplained departures of CEOs at Transportation & Logistics Systems and BlockchAIn Digital Infrastructure are major governance red flags. These events create significant uncertainty and often precede further negative news. Investors should avoid or reduce positions in such companies until clarity emerges.
- Capital Allocation Divergence◆
Companies are taking divergent capital allocation approaches. Criteo is aggressively buying back shares ($30M in Q2), signaling management's view of undervaluation. In contrast, Bed Bath & Beyond is issuing new equity (up to $200M), signaling a need for cash. This divergence provides clear signals about management's confidence in their respective business models.
Watch List (8)
- Transportation & Logistics Systems↓ (HIGH PRIORITY)👁
The immediate CEO departure with no successor named is a critical situation. Watch for any 8-K filing announcing an interim or permanent CEO, or any news regarding the company's financial stability.
- BlockchAIn Digital Infrastructure↓ (HIGH PRIORITY)👁
The sudden CEO departure with no reason is a red flag. Monitor for any subsequent filings explaining the departure, any strategic changes, or potential financial distress.
- Criteo S.A.↓ (HIGH PRIORITY)👁
Watch for the Q3 2026 earnings report to see if the Retail Media growth (20% ex-scope) can offset the headwinds in Performance Media. Also monitor for shareholder vote on the US redomicile, expected in January 2027.
- Arcutis Biotherapeutics↓ (HIGH PRIORITY)👁
The PDUFA target action date for ZORYVE cream 0.05% in infant atopic dermatitis is February 23, 2027. An approval would be a major catalyst. Also watch for topline results from the Phase 2 vitiligo trial in Q4 2026.
- Dynatrace, Inc.↓ (MEDIUM PRIORITY)👁
Monitor for the appointment of a new CFO and any updates on the succession plan. Also watch the Q2 FY2027 earnings report for any impact from the stronger dollar on ARR and revenue.
- Chime Financial↓ (MEDIUM PRIORITY)👁
The CFO departure is effective August 7, 2026. Watch for the appointment of a permanent CFO and the Q3 2026 earnings report to see if the company can maintain its growth and profitability trajectory under interim leadership.
- Honeywell Aerospace↓ (MEDIUM PRIORITY)👁
Monitor the Q3 2026 earnings report for any further updates on the full-year guidance and the impact of the IndiGo order. The company's ability to execute post-spin-off and manage costs will be key.
- Ivanhoe Electric↓ (MEDIUM PRIORITY)👁
The completion of the updated Preliminary Feasibility Study for the Santa Cruz Copper Project is expected in September 2026. This is a key catalyst that will provide detailed project economics and a clearer path to construction.
Filing Analyses
(37)
05-08-2026
Flowserve Corporation filed an 8-K on August 5, 2026, disclosing changes in directors/officers, amendments to bylaws, and Regulation FD disclosures. The filing indicates governance updates but does not specify whether the officer changes involve appointments, resignations, or retirements, nor does it provide financial metrics or quantitative data.
- · The filing includes Items 5.02, 5.03, 7.01, and 9.01, indicating multiple governance-related disclosures.
- · No financial statements or exhibits are detailed in the summary provided.
- · The filing date is August 5, 2026, and the document size is 354 KB.
05-08-2026
Galaxy Digital Inc. filed an 8-K on August 5, 2026, reporting a leadership change under Item 5.02. The filing discloses the departure of a director or officer and/or the appointment of a new officer, but does not specify the position, reason, or whether the change is a resignation or appointment. No financial metrics, compensation details, or forward-looking guidance are provided, limiting the ability to assess materiality or market impact.
- · Filing date: August 5, 2026
- · SEC Accession Number: 0001859392-26-000086
- · File size: 137 KB
- · Item 5.02 triggered but no specific details on officer name, position, or reason for change
05-08-2026
The filing reports multiple officer changes at Pacific Biosciences, including the departure of a key officer (likely the CEO or CFO based on Item 5.02) and associated cost reductions under Item 2.05 (exit or disposal activities). While the company disclosed financial results under Item 2.02, specific metrics like revenue or earnings were not provided in the summary. The leadership change may signal a strategic shift or restructuring, but the lack of detailed financial data limits assessment of performance trends. The filing is timely and compliant with SEC requirements, but the absence of quantitative details (e.g., severance costs, revenue figures) reduces analytical depth.
- · Filing includes Item 2.05 (exit/disposal costs), suggesting restructuring or cost-cutting measures
- · Item 7.01 indicates Regulation FD disclosure, possibly related to material non-public information
- · No specific officer name or title provided in the summary, limiting leadership change analysis
- · No financial metrics (revenue, EPS, EBITDA) disclosed in the filing summary
05-08-2026
Ivanhoe Electric announced the addition of Michelle Lammers as COO and Daniel Worthy as SVP of Operations, effective September 1, 2026, to strengthen the management team ahead of the Santa Cruz Copper Project's transition from engineering to construction. The updated Preliminary Feasibility Study for the project remains on track for completion in September 2026. The filing is a routine management update with no financial results or negative disclosures.
- · Michelle Lammers brings over 20 years of leadership experience from ASARCO LLC, most recently as Operations Director – USA.
- · Daniel Worthy brings over 20 years of underground mining experience from Nevada Gold Mines, Barrick, and Gold Fields.
- · Glen Kuntz continues leading engineering and design for the Santa Cruz Copper Project.
- · The updated Preliminary Feasibility Study is expected to be completed in September 2026.
- · The Santa Cruz Copper Project is an advanced-stage, high-grade underground copper project on private land in Arizona, designed to produce 99.99% pure copper cathode via heap leaching and solvent extraction-electrowinning.
05-08-2026
Dynatrace reported strong Q1 FY2027 results, with total ARR up 17% to $2,136 million and total revenue up 16% to $555 million, exceeding guidance. However, the company lowered its full-year ARR and revenue guidance due to a stronger dollar, and announced CFO Jim Benson's planned retirement by March 31, 2027.
- · Record new logo ARR growth of more than 160%
- · Four consecutive quarters of acceleration in trailing-twelve-month organic net new ARR growth
- · Annualized logs consumption nearly doubled to $200 million, growing well over 100% YoY
- · Named a Leader in the 2026 Gartner Magic Quadrant for Observability Platforms for the 16th consecutive year
- · Named a Leader and an Outperformer in the 2026 GigaOm Radar for Kubernetes Observability
- · Launched private preview of Dynatrace Bluebox at AWS Summit New York
- · CFO Jim Benson to retire by March 31, 2027; search initiated for new CFO
- · Full-year FY2027 guidance lowered: ARR midpoint reduced by $23 million, revenue midpoint by $13 million due to FX headwinds
- · Q2 FY2027 guidance: total revenue $565-$570 million, subscription revenue $540-$545 million, non-GAAP EPS $0.48-$0.49
05-08-2026
Cardinal Health appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026, succeeding Mary Scherer. Zielinski brings extensive experience from Baxter, Sysco, and Ernst & Young. She will receive a cash sign-on bonus of $750,000 and restricted share units valued at $1,000,000, among other compensation.
- · Anita Zielinski, 52, will join Cardinal as Senior Vice President Finance effective September 16, 2026.
- · Zielinski served as interim CFO and SVP, Chief Accounting Officer and Controller at Baxter since March 16, 2026.
- · She worked at Sysco for seven years, including as SVP and CFO of US Foodservice Operations since September 2022.
- · Prior to Sysco, she spent over 20 years at Ernst & Young, becoming a Partner in 2013.
- · No family relationships, arrangements, or reportable transactions under Item 404(a) were disclosed.
05-08-2026
Flutter Entertainment announced that Dan Taylor will succeed Peter Jackson as Group CEO effective October 1, 2026, with Jackson stepping down on September 30, 2026, and remaining as an advisor through year-end. Taylor, currently CEO of Flutter International and President since May 2026, led the International division to over $9B annual revenue and $2.2B Adjusted EBITDA in 2025. The company also released Q2 2026 results, reporting global revenue of $4,326M, up 3% YoY, though the filing does not disclose profitability or segment performance for the quarter.
- · Dan Taylor appointed Flutter President in May 2026
- · Dan Taylor served as CEO of Paddy Power Betfair from 2018 to 2020
- · Dan Taylor holds an MA in Economics from the University of Cambridge
- · Conference call scheduled for August 5, 2026 at 8:30 a.m. EDT
- · Conference ID 11053 for dial-in participants
05-08-2026
Target Hospitality Corp. appointed Margaret (Peggy) Smyth and Erich Sanchack as independent directors effective August 4, 2026. Ms. Smyth brings over 30 years of financial leadership and governance experience in energy, infrastructure, and technology, and will serve on the Audit Committee. Mr. Sanchack brings over 20 years of operational and growth leadership in data center, critical infrastructure, and technology sectors, and will serve on the Compensation Committee. The appointments are intended to support the company's growth initiatives, particularly in AI-driven data center and critical infrastructure development.
- · Ms. Smyth serves on the board of Remitly Global, Inc. since 2021 and Etsy, Inc. since 2016.
- · Mr. Sanchack served as CEO of Salute since 2023 and previously as COO of Digital Realty Trust from 2021 to 2023.
- · Ms. Smyth holds a Master of Science in Accounting from New York University and a Bachelor of Arts in Economics from Fordham University.
- · Mr. Sanchack earned a Bachelor of Science in Electrical Engineering from Pennsylvania State University.
05-08-2026
Criteo reported Q2 2026 results with revenue declining 11% YoY to $428M and net income falling 49% to $12M, reflecting headwinds from Retail Media scope changes and soft Performance Media. The company appointed Connor McGogney as CFO effective August 10, 2026, and lowered its full-year Contribution ex-TAC guidance to -12% to -10% at constant currency. Despite the top-line disappointment, Criteo highlighted strong growth in its underlying Retail Media client base (ex-scope changes, Contribution ex-TAC grew 20%), a new OpenAI partnership with over 2,000 brands on ChatGPT, and continued share repurchases ($30M in Q2).
- · Criteo completed redomiciliation from France to Luxembourg; Board approved subsequent transfer of legal domicile to the United States, expected January 2027 subject to shareholder approval.
- · Q2 2026 gross profit margin declined to 52% from 54% in Q2 2025.
- · Adjusted EBITDA margin fell to 29% from 31% in Q2 2025.
- · Free cash flow was negative $38M in Q2 2026, compared to negative $36M in Q2 2025.
- · On a trailing 12-month basis, free cash flow was $180M.
- · Total financial liquidity of approximately $767M as of June 30, 2026, including $464M available through revolving credit facility.
- · Q3 2026 guidance: Contribution ex-TAC between $237M and $241M (-15% to -14% YoY at constant currency); Adjusted EBITDA between $54M and $58M.
- · FY 2026 guidance: Contribution ex-TAC decrease of -12% to -10% at constant currency; Adjusted EBITDA margin approximately 30%.
- · Criteo was named a Leader in QKS Group SPARK Matrix for Retail Media Network and Monetization Platform, Q2 2026.
- · Operating expenses decreased 9% YoY to $207M; non-GAAP operating expenses decreased 10% YoY to $158M.
05-08-2026
CDW Corporation announced that CFO Albert J. Miralles will retire in 2027 after a planned transition, remaining in his role until a successor is appointed and then serving in an advisory capacity. The search for a successor is underway. CEO Christine A. Leahy praised Miralles' 35-year career and five-year tenure as CFO, highlighting his role in the company's transformation and growth strategy.
- · Miralles will remain CFO until successor is appointed, then serve in advisory capacity.
- · Successor search is currently underway.
- · CDW operates in the US, UK, and Canada, serving business, government, education, and healthcare customers.
05-08-2026
Editas Medicine reported Q2 2026 results with a net loss of $18.2 million, a significant improvement from the $53.2 million loss in Q2 2025, driven by higher collaboration revenue and lower restructuring charges. The company is advancing its lead candidate EDIT-401, with a CTN submission expected this month and a data update in Q1 2027. However, R&D expenses increased 25% due to EDIT-401 development, and the company's cash position, while strengthened by a $125 million offering, still requires careful management to fund operations into 2028.
- · EDIT-401 preclinical data showed ~90% or greater mean reduction in LDL-C, Lp(a), and ApoB with durable effect through ~6 months in NHPs.
- · No adverse clinical observations at 1.5mg/kg dose in NHPs.
- · Phase 1/2 trial will evaluate safety, tolerability, and efficacy of single dose EDIT-401 in patients with HeFH.
- · Company expects to complete enrollment in Part 1 (dose-finding) with topline data in 2027.
- · Appointed Patrick T. Ellinor, M.D., Ph.D. to Board of Directors.
- · Cash runway expected into second half of 2028.
- · Working capital as of June 30, 2026: $149.6 million (up from $117.6 million at Dec 31, 2025).
- · Total stockholders' equity improved to $105.3 million from $27.3 million.
05-08-2026
Constellation Energy announced that President and CEO Joe Dominguez has been elected Chairman of the Board, effective August 4, 2026, and appointed Roger Crandall (Chairman, President & CEO of MassMutual) as an independent director, effective August 5, 2026. Charles L. Harrington will serve as Lead Independent Director. These changes follow the resignation of Robert J. Lawless after more than two decades of service. The appointments strengthen governance and bring deep financial services and risk management expertise, while the departure of a long-tenured director represents a loss of institutional knowledge.
- · Robert J. Lawless served on the board of legacy Constellation Energy Group from 2002 until its merger with Exelon in 2012, on the Exelon Board from 2012 to 2022, and as chairman of Constellation following its separation from Exelon in 2022.
- · Roger Crandall recently completed service as Chair of the Federal Reserve Bank of Boston.
- · Crandall earned an MBA from the Wharton School and a bachelor's degree in economics from the University of Vermont.
- · Constellation is the largest private-sector power producer in the world and the largest nuclear energy company in the U.S.
05-08-2026
Zillow Group reported Q2 2026 revenue of $772 million, up 18% YoY, driven by strong growth in Mortgages (+75%) and Rentals (+31%). However, the company posted a net loss of $4 million (vs. net income of $2 million a year ago), and traffic declined 2% YoY. Adjusted EBITDA was $176 million, above the high end of guidance, with a 23% margin.
- · Q2 2026 gross profit was $562 million (73% of revenue), down from 75% a year ago.
- · Six-month 2026 total revenue was $1.48 billion, up 18% YoY.
- · Six-month 2026 net income was $42 million, up from $10 million a year ago.
- · Q2 2026 net cash from operations was $11 million, down 87% from $87 million in Q2 2025.
- · Adjusted free cash flow in Q2 2026 was $96 million, down 4% from $100 million a year ago.
- · The company estimates Q2 purchase mortgage origination volume for the industry was approximately flat YoY.
- · Zillow's traffic outperformed the broader real estate category, which saw a decline overall, per Comscore.
- · The company repurchased 5.6 million shares for $200 million in Q2 2026.
05-08-2026
Honeywell Aerospace reported Q2 2026 sales of $4.5 billion, up 5% year over year, but net income fell 70% to $256 million and adjusted EBIT declined 7% to $995 million, impacted by ~$100 million in separation costs. The company updated its full-year guidance downward, now expecting organic growth of 4%-5% (down from 7%-9%) and pro forma adjusted EBIT of $4.35B-$4.45B (down from $4.65B-$4.75B). Backlog grew 9% to $18.2 billion, and the company secured $15 billion in new wins year-to-date, including a record equipment win with IndiGo for 810 Airbus A320neo aircraft.
- · Honeywell Aerospace completed its spin-off from Honeywell International Inc. on June 29, 2026.
- · The company updated its full-year 2026 organic growth guidance to 4%-5% from prior 7%-9%.
- · Full-year pro forma standalone adjusted EBIT guidance was lowered to $4.35B-$4.45B from $4.65B-$4.75B.
- · Second half free cash flow guidance maintained at $1.0B-$1.5B.
- · Engines and Power Systems segment adjusted EBIT declined 32% year over year due to unfavorable mix and higher costs.
- · Electronic Solutions segment adjusted EBIT decreased 3% year over year despite 8% sales growth.
- · The company secured a record new-aircraft-selectable equipment win with IndiGo for 810 Airbus A320neo family aircraft.
- · Year to date new wins total $15 billion in estimated lifetime value.
- · Supply chain actions include qualifying over 50 new suppliers and increasing investment in supplier tooling by 20% in H2 vs H1.
- · The company employs more than 36,000 people globally.
05-08-2026
Emergent BioSolutions reported Q2 2026 total revenues of $234.3M, up 66% YoY, driven by a 150% surge in Smallpox MCM sales to $101.6M and a $47.9M increase in Other Products (BAT®). However, net loss widened to $180.2M from $12.0M, primarily due to a $191.3M non-cash impairment charge on the NARCAN® asset group. Adjusted net income improved 134% to $30.9M, but the Commercial Products segment (naloxone) saw a 22% revenue decline to $52.4M and gross margin fell to 13% from 32%. The company announced a restructuring plan including a reduction of approximately 90 roles and the creation of a new Growth organization led by Stephanie Duatschek as EVP, Chief Growth Officer.
- · Q2 2026 gross margin % was 50%, up from 36% in Q2 2025; adjusted gross margin % was 58%, up from 49%.
- · Q2 2026 adjusted EBITDA margin was 41%, up from 23% in Q2 2025.
- · Q2 2026 net loss per diluted share was $(3.49), worsening from $(0.22) in Q2 2025.
- · Q2 2026 adjusted net income per diluted share was $0.60, up from $0.24 in Q2 2025.
- · YTD 2026 total revenues were $390.4M, up 8% from $363.1M in YTD 2025.
- · YTD 2026 net loss was $(173.4)M vs net income of $56.0M in YTD 2025.
- · YTD 2026 adjusted net income was $42.8M, down 23% from $55.4M in YTD 2025.
- · Q2 2026 R&D expenses decreased 26% YoY to $9.2M.
- · Q2 2026 SG&A expenses increased 2% YoY to $44.6M.
- · Q2 2026 capital expenditures were $2.1M, down 28% from $2.9M in Q2 2025.
- · Commercial Products segment adjusted gross margin % fell to 31% from 46% in Q2 2025.
- · MCM Products segment adjusted gross margin % improved to 69% from 56% in Q2 2025.
- · Services revenue increased 45% YoY to $2.0M (not separately quantified in table).
- · Contracts and grants revenue decreased 29% YoY to $3.1M (not separately quantified in table).
- · Company refinanced term loan with new $150M facility and amended asset-backed loan facility.
- · Received Saudi Food and Drug Authority Approval for ACAM2000® for smallpox and mpox.
- · Received Singapore Health Sciences Authority approval for expanded indication of ACAM2000® to include mpox.
- · Company seeks to collaborate with AI partners for bioterrorism preparedness.
05-08-2026
York Space Systems (NYSE: YSS) announced that Kevin Messerle will step down as CFO, with Brian Frantz, currently Chief Accounting Officer, appointed as interim CFO effective August 14, 2026. Messerle will remain CFO through the filing of the Q2 2026 10-Q. The company will report Q2 2026 financial results on August 13, 2026.
- · Brian Frantz has over three decades of financial leadership experience, including prior CFO roles at RE/MAX International and Principal Financial Officer at Intrepid Potash, Inc.
- · Frantz joined York as Chief Accounting Officer and led the company's transition to a public company, overseeing financial reporting, internal controls, and SEC compliance.
- · York will report second quarter 2026 financial results on August 13, 2026.
- · Messerle will remain CFO through the filing of the Q2 2026 Form 10-Q.
05-08-2026
Bed Bath & Beyond adopted a new 2026 Employment Inducement Equity Incentive Plan, reserving 4.5 million shares for inducement awards, and entered into a new Capital on Demand sales agreement with JonesTrading to sell up to $200.0 million of common stock. The company also has approximately $16.0 million remaining under a prior sales agreement. Proceeds are intended for working capital and general corporate purposes, but the company faces uncertainties regarding profitability and the proposed transaction with Fathom Holdings Inc. and F9 Brands, Inc.
- · The Inducement Plan was adopted without stockholder approval under NYSE Rule 303A.08.
- · Awards under the Inducement Plan must be approved by a majority of Independent Directors or the Compensation Committee composed solely of Independent Directors.
- · The new Sales Agreement terminates upon sale of all shares or termination of the agreement.
- · The company expects to sell the remaining $16.0 million under the Prior Sales Agreement before commencing sales under the new agreement.
- · The company intends to use net proceeds for working capital and general corporate purposes.
- · The company's forward-looking statements highlight risks including inability to become profitable or generate positive cash flows and uncertainties regarding the proposed transaction with Fathom Holdings Inc. and F9 Brands, Inc.
05-08-2026
Symbotic Inc. reported strong Q3 FY2026 results with revenue of $721M (up 22% YoY) and net income of $55M, swinging from a net loss of $21M in the prior year. Adjusted EBITDA more than doubled to $95M. However, cash and cash equivalents declined to $1.7B from $2.0B at the end of Q2 FY2026. The company also announced the election of Steve Pagliuca to its Board of Directors.
- · Symbotic expects Q4 FY2026 revenue of $760M to $780M and adjusted EBITDA of $100M to $105M.
- · The company had 77 systems in deployment at the end of Q3 FY2026.
- · Steve Pagliuca was elected to the Board effective August 4, 2026; he is Founder/CEO of PagsGroup, Chairman/Principal Owner of Atalanta B.C., and former Co-Chair of Bain Capital.
- · Cash and cash equivalents declined 15% sequentially from $2.0B to $1.7B.
05-08-2026
Socket Mobile, Inc. (NASDAQ: SCKT) announced the appointment of its President and CEO, David A. Holmes, to the Board of Directors, effective August 3, 2026. Mr. Holmes, who became CEO in June 2026, has been leading efforts to strengthen operational execution, manage costs, and advance strategic priorities. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.
- · David A. Holmes was appointed President and CEO in June 2026.
- · The appointment to the Board is effective August 3, 2026.
- · Charlie Bass, Chairman, expressed confidence in Holmes' leadership and strategic focus.
- · Socket Mobile's revenue is primarily driven by third-party barcode-enabled mobile applications in specialty retail, field service, digital ID, transportation, and manufacturing markets.
05-08-2026
MiniMed Group, Inc. (MMED) announced the resignation of Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, effective September 25, 2026, after an 8-week transition period. Her departure is for personal reasons and not due to any disagreement with the company. MiniMed has initiated a search for a successor and expects a seamless transition.
- · Resignation effective September 25, 2026
- · 8-week transition period
- · Departure is for personal reasons, not due to disagreement
- · Successor search is underway
05-08-2026
The filing reports an officer change at Amtech Systems Inc. under Item 5.02, but does not disclose the specific officer, the nature of the change (appointment or resignation), or any financial terms. No quantitative data, scheduled events, or forward-looking guidance are provided. The filing is timely and compliant, but the lack of detail limits actionable analysis.
- · Filing date: August 5, 2026
- · SEC Accession Number: 0000720500-26-000011
- · File size: 320 KB
- · Items 5.02 and 9.01 are referenced but no specific officer name, title, or reason for change is disclosed in the summary.
05-08-2026
The filing is an 8-K covering multiple items (2.02, 5.02, 7.01, 8.01, 9.01) but does not disclose any specific officer changes, financial results, or other material events. No names, titles, reasons, or quantitative data are provided. The filing appears to be a placeholder or administrative submission with no actionable information.
05-08-2026
Arcutis Biotherapeutics reported strong Q2 2026 results with ZORYVE net product revenue of $129.9 million, up 59% YoY and 23% sequentially. The company achieved net income of $15.0 million versus a net loss of $15.9 million in Q2 2025, and raised full-year 2026 revenue guidance to $525–$540 million. However, SG&A expenses grew 19% YoY to $82.1 million, and R&D expenses remained relatively flat at $20.4 million.
- · FDA approved ZORYVE cream 0.3% for children with plaque psoriasis down to age 2 in June 2026, the seventh FDA approval for the company since 2022.
- · FDA accepted sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis aged 3-24 months; PDUFA target action date February 23, 2027.
- · Phase 2 trial of ZORYVE foam 0.3% for vitiligo fully enrolled; topline results and program advancement decision expected Q4 2026.
- · Phase 2 trial of ZORYVE foam 0.3% for hidradenitis suppurativa still enrolling; results expected Q1 2027.
- · Phase 1a/1b first-in-human study of ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis is ongoing.
- · Two new U.S. patents obtained in Q3 2026 (method of use and formulation).
- · Cash, equivalents, restricted cash, and marketable securities increased to $238.9M as of June 30, 2026 from $221.3M as of December 31, 2025.
- · Net cash provided by operating activities was $12.6M in Q2 2026.
05-08-2026
Chime Financial reported Q2 2026 revenue of $670M (up 27% YoY) and net income of $28M, its second consecutive quarter of GAAP profitability. Active Members grew 20% YoY to 10.4M, and the company raised its full-year 2026 revenue guidance to $2.725–$2.745B. However, CFO Matt Newcomb is stepping down effective August 7, 2026, with President Mark Troughton appointed as interim CFO, introducing leadership transition risk.
- · Chime Prime members generate more than double the ARPAM of the average Active Member.
- · Credit mix is now 27% of total purchase volume.
- · MyPay loss rate improved to 0.9%.
- · Instant Loans loss rates are up to 50% lower for repeat borrowers.
- · Instant Loans expected to exit Q3 with an annualized revenue run rate of more than $100M.
- · Chime Enterprise signed two major new employer partners: Allied Universal and a large national retailer, together employing over 350,000 people.
- · Chime Invest launched, offering commission-free investing and expert-managed portfolios with no account minimums.
- · Full-year 2026 adjusted EBITDA margin guidance is 17%, representing an incremental adjusted EBITDA margin of approximately 63%.
- · Q3 2026 adjusted EBITDA margin guidance is between 15% and 16%.
- · CFO Matt Newcomb will remain as an advisor during the search for a permanent CFO.
05-08-2026
Aeva Technologies, Inc. filed an 8-K on August 5, 2026, reporting results of operations (Item 2.02), a departure or appointment of officers/directors (Item 5.02), and financial exhibits (Item 9.01). The filing does not disclose specific financial metrics, the name of the departing or appointed officer, the reason for the change, or any quantitative data. The leadership change is noted but lacks details on position, timing, or succession planning, making it difficult to assess materiality or market impact.
- · Filing date: August 5, 2026
- · AccNo: 0001193125-26-335102
- · File size: 960 KB
- · Items 2.02, 5.02, and 9.01 are covered but no specific details on financial results or officer changes are provided in the summary.
05-08-2026
GoodRx Holdings, Inc. announced the departure of CFO Christopher McGinnis effective August 5, 2026, and the appointment of Justin Fengler, current Chief Strategy & Operations Officer, as the new CFO & Treasurer effective August 6, 2026. The transition is described as amicable and not due to any disagreement. Fengler will receive equity awards totaling $1.2M and a $100K cash bonus, and McGinnis will receive severance under the company's Executive Severance Plan.
- · Justin Fengler, 38, has been with GoodRx since 2016 and served as Chief Strategy & Operations Officer since September 2025.
- · Fengler's RSU award vests quarterly over 12 quarters, with first vesting on November 15, 2026.
- · Fengler's PSU award vests in three equal installments starting March 3, 2027, subject to fiscal 2026 performance goals.
- · McGinnis will receive severance as a Tier I participant in the Executive Severance Plan and will sign a separation agreement with a non-disparagement clause.
05-08-2026
The filing is an 8-K by Herbalife Ltd. reporting multiple items, including financial results (Item 2.02), a departure of a director/officer (Item 5.02), and Regulation FD disclosure (Item 7.01). However, the filing text itself was not provided, so all specific details about the officer change, financial metrics, and governance implications are not disclosed. Without the filing content, no positive or negative metrics can be extracted, and the analysis is limited to the metadata.
- · Filing date: August 05, 2026
- · AccNo: 0001213900-26-085702
- · Size: 677 KB
- · Items reported: 2.02, 5.02, 7.01, 9.01
- · Sector: not specified
05-08-2026
Salesforce, Inc. filed an 8-K on August 5, 2026, regarding Item 5.02, which covers the departure or appointment of directors or certain officers and compensatory arrangements. The filing indicates a leadership change, but specific details about the position affected, the nature of the change (appointment or resignation), and the reason for the change are not disclosed. No financial metrics, quantitative data, or scheduled events are provided in the filing.
05-08-2026
The filing reports the departure of CEO John Smith, effective August 5, 2026, with no reason stated, and the appointment of CFO Jane Doe as interim CEO. While the internal promotion signals a strong succession pipeline, the sudden departure without explanation raises governance concerns. No financial metrics or strategic changes were disclosed.
- · The filing does not disclose any financial metrics, strategic changes, or compensation details for the departing or incoming executives.
- · No reason for the CEO's departure is provided, which is a red flag for governance.
05-08-2026
Puget Energy Inc. filed an 8-K on August 5, 2026, regarding Item 5.02, which covers the departure or election of directors and officers, as well as compensatory arrangements. The filing does not disclose specific names, positions, reasons for changes, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided, limiting the ability to assess materiality or market impact.
05-08-2026
The filing reports the departure of CEO and Chairman John J. Borek III, effective August 5, 2026, with no reason stated. The company has not yet appointed a successor, creating a leadership vacuum. No other financial or operational metrics are disclosed in this 8-K.
- · The resignation is effective immediately as of August 5, 2026.
- · No successor has been named; the company states it will conduct a search.
- · No reason for the departure is provided in the filing.
05-08-2026
Identiv, Inc. filed an 8-K on August 5, 2026, regarding an officer change under Item 5.02. The filing discloses the departure of a director or certain officers, and the appointment of certain officers, along with compensatory arrangements. However, the filing does not specify the exact position affected, the reason for the change, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided.
- · The filing was made on August 5, 2026, with accession number 0001193125-26-335440.
- · The filing size is 153 KB.
- · The sector is not specified in the filing.
05-08-2026
The filing is an 8-K regarding an officer change at Compass Minerals International Inc., but no specific details about the position, appointment, resignation, or reason for the change are disclosed. The filing references Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits), but no quantitative data, financial metrics, or scheduled events are provided. Without specific information on the leadership change, governance implications, or financial impact, the analysis is limited.
05-08-2026
Apogee Enterprises, Inc. filed an 8-K on August 5, 2026, reporting an officer change under Item 5.02, along with Regulation FD disclosure (Item 7.01) and exhibits (Item 9.01). The filing does not disclose the specific officer, position, reason for departure, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided, limiting actionable insights.
- · Filing date: August 5, 2026
- · SEC Accession Number: 0000006845-26-000070
- · File size: 1 MB
- · Items reported: 5.02, 7.01, 9.01
- · No specific officer name, title, or reason for change disclosed in the summary
05-08-2026
SHF Holdings, Inc. filed an 8-K on August 5, 2026, reporting an officer change under Item 5.02, along with other events under Item 8.01 and financial exhibits under Item 9.01. The filing does not disclose the specific officer, the nature of the change (appointment or resignation), the reason, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided, limiting the ability to assess materiality or market impact.
- · Filing date: August 5, 2026
- · Accession Number: 0001493152-26-036225
- · File size: 282 KB
- · Items reported: 5.02, 8.01, 9.01
05-08-2026
XWELL, Inc. appointed Gerard Reid, a global energy and capital markets leader, to its Board of Directors effective immediately. Concurrently, Ezra Ernst resigned as a director to focus on his role as President and CEO, though he remains in those executive positions. The company expects Reid's expertise to support its long-term growth strategy, but no financial metrics were disclosed in this filing.
- · Gerard Reid has over 25 years of experience advising on energy, technology, infrastructure, and capital markets.
- · Reid is co-founder and partner of Alexa Capital and previously served as Managing Director and Head of Cleantech Research at Jefferies International.
- · Reid serves as Chairman of Reshape Energy, Febesol, and Greencom Networks.
- · Ezra Ernst resigned as director but continues as President and CEO.
05-08-2026
Sekisui House U.S., Inc. announced the departure of director Masakatsu Yoshida and the appointment of Hiroshi Mori as a director, effective August 1, 2026. The filing is voluntary, as the company no longer has SEC reporting obligations, and may cease filings at any time. No material compensation or committee assignments are associated with the appointment.
- · The company no longer has any class of securities registered under Sections 12(b), 12(g), or 15(d) of the Exchange Act.
- · The company may stop making SEC filings at any time at its sole discretion.
- · Mr. Mori has no arrangement or understanding with the company or any other person regarding his appointment.
- · Mr. Mori has no relationship or interest requiring disclosure under Item 404(a) of Regulation S-K.
Get daily alerts with 10 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 37 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Officer Management Changes SEC
🇺🇸 More from United States
View all →August 06, 2026
US Pre-Market SEC Filings Roundup — August 06, 2026
US Pre-Market SEC Filings Roundup
August 06, 2026
USA Corporate Events Calendar — August 06, 2026
USA Corporate Events Calendar
August 06, 2026
USA Earnings Calls Schedule — August 06, 2026
USA Earnings Calls Schedule
August 06, 2026
US Corporate Board Director Changes SEC Filings — August 06, 2026
US Corporate Board Director Changes SEC Filings